Ring Therapeutics Stock

Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.

Sign up today and learn more about Ring Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Ring Therapeutics Stock

Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company is expanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases.

Funding History

January 2020$50.0M
July 2021$117M
March 2023$86.5M


Chief Technology Officer

Konstantin Konstantinov

Independent Director

David Epstein

Chief Scientific Officer

Yong Chang

Chairman & Founder

Avak Kahvejian

Chief Regulatory Officer

Kevin B. Johnson

Board Member

B. Lynne Parshall

Board Member

Torben Straight Nissen


Tuyen Ong

Co-Founder and Advisor

Erica Weinstein


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: